Study: DTP Increases Mortality in Infants 5 to 10 Fold Compared to Unvaccinated

For years public health advocates wanted the CDC and WHO to run studies on vaccinated vs. unvaccinated populations and compares health outcomes. A team of Native scientists have conducted such a study and the consequences are alarming. The study, financed in part by the Danish authorities and lead by Dr. Soren Wengel Mogensen, was published in January in EBioMedicine.

The data suggest that the DTP vaccine reduces infections from those 3 germs, but data also shows that children are more likley to die from other causes. Mogensen’s team discovered that DTP inoculated African Americans had 5-10 times higher mortality than their unvaccinated peers.

 Though protective against the target disease, DTP may increase susceptibility to unrelated infections… DTP was associated with 5-fold higher mortality than being unvaccinated.  No prospective study has shown beneficial survival effects of DTP.” – Vaxxed vs. Non-Vaxxed Study

Related: How Plumbing (Not Vaccines) Eradicated Disease

Mogensen and his colleagues hypothesize that the DTP vaccine weakens the immune system, which supports the conclusions of prior studies. An earlier study by Dr. Peter Aaby, on the introduction of DTP in rural Guinea-Bissau, indicated a 2-fold greater mortality among vaccinated kids. The Aaby report is just one of many studies that adopted kids and documented vaccination status. All of them suggested that DTP-vaccinated kids died at rates far exceeding mortality.

In the primary analysis, DTP-vaccinated infants experienced mortalities five times greater than DTP-unvaccinated infants.  Mortalities to vaccinated girls were 9.98 times those among females in the unvaccinated control group, while mortalities to vaccinated boys were 3.93 times the controls.  Oddly, the scientists found that children receiving the oral polio vaccine simultaneously with DTP fared much better than children who did not.  The OPV vaccine appeared to modify the negative effect of the DTP vaccine, reducing mortalities to 3.52 times those experienced among the control group.  Overall, mortalities among vaccinated children were 10 times the control group when children received only the DTP.” – Robert F Kennedy

Related: How To Detoxify and Heal From Vaccinations – For Adults and Children

Moreover, Mogensen and his colleagues observe that the research reviewed by SAGE probably exacerbated the deadly effect of the DTP vaccine due to unusually high mortality in the control groups,

Unvaccinated children in these studies have usually been frail children too sick or malnourished to get vaccinated and the studies may therefore have underestimated the negative effect of DTP”. The Mogensen study sought to avoid this pitfall by removing orphans and children from the control group and the research group and by utilizing controls. It included children who had been breastfed. All of the infants were healthy at the right time of vaccination. Nevertheless, the Mogensen authors went longer and point out that, even in their analysis, the unvaccinated kids had status. They conclude that, “The estimate from the natural experiment may therefore still be conservative.”

Recommended: Lyme Disease – Holistic Protocol to Completely Rebuild the Immune System

From the early 1980s, a cascade of lawsuits filed throughout the United States drove DTP manufacturers and threatening to shut down production of vaccines and the DTP shot. That threat led the U.S. Congress to bestow legal immunity on vaccine makers during the National Childhood Vaccine Injury Program from 1986, conducted in December, 1987, from the rollout of “Vaccine Court.” After the recommendation from the Institute of Medicine, thimerosal was removed by vaccine manufacturers from the American DTaP involving 2001-2003. But, multi-dose DTP vaccines given to thousands of children across the African continent carry on to contain huge doses of thimerosal (25mcg of ethylmercury per booth) that exceed the EPA’s maximum exposure levels by many times. Neither the CDC nor the WHO has ever published a vaccinated vs. unvaccinated study that will be necessary to determine the total health consequences of the potent toxin on African children. The Mogensen report is a call for such a research.

The authors close with a bracing rebuke to people health labs,

“It should be of concern that the effect of routine vaccinations on all-cause mortality was not tested in randomized trials.  All currently available evidence suggests that DTP vaccine may kill more children from other causes than it saves from diphtheria, tetanus or pertussis.  Though a vaccine protects children against the target disease it may simultaneously increase susceptibility to unrelated infections.”

https://youtu.be/cx1VDqvDXjE

Related Reading:
Source:


Pentavalent Vaccines – When Did Vaccines Adopt the Bulk Model?

Vaccines designed to provide immunity to three diseases in one shot, like the MMR and DTP, have become the industry standard. It’s incredibly difficult to find single doses of these vaccines. The development and availability of five-in-one vaccines are more likely to make single dose vaccines even more of a rarity. Welcome to the age of pentavalent vaccines.

What’s the Skinny?

The Global Alliance for Vaccines and Immunisations (GAVI) introduced pentavalent vaccines in 2001 (although pharmaceutical giant Sanofi Pasteur first licensed a pentavalent vaccine in 1993). The most commonly used pentavalent vaccines combine the DTP (diphtheria, tetanus, and pertussis) with vaccines designed to provide immunity for Hepatitis B and Haemophilus Influenza type-B (Hib), the bacteria that causes meningitis, pneumonia, and otitis. A typical vaccine schedule for pentavalent vaccines calls for the child to receive shots at 6, 10, and 14 weeks.

GAVI has been a big supporter of pentavalent vaccines and currently supplies 73 of the world’s poorest countries with these vaccines. These countries are primarily in Africa and across Asia, with Albania, Moldova, and Guyana also included in the list. In the 15 years since the introduction of pentavalent vaccines, their coverage has grown from 1% to 68% of people vaccinated in supported countries.

The Belle of the Ball

Why wouldn’t these vaccines be a priority? From the medical and pharmaceutical community’s viewpoint, a 5 in 1 vaccine provides many benefits. It’s easier to administer, creates less syringe waste, can be produced more quickly, and is cheaper to ship.

Pentavalent vaccines also increase coverage. Prior to the GAVI in 2000, fewer than 10% of low-income countries were giving the hepatitis B vaccine and even fewer were immunizing for Haemophilus Influenza type-B. The numbers vaccinated were minuscule in comparison to the 68% of people covered in these countries 15 years after the introduction of the pentavalent program.

Not Without Issues

The GAVI pentavalent vaccine program has been a success, although there have been bumps along the road. Quinvaxem, the most commonly used pentavalent vaccine, was suspended in Vietnam after nine children died post-vaccination in 2013. While Quinvaxem was reinstated within the same year in Vietnam, other countries in the region like Sri Lanka, India, and Bhutan also expressed safety concerns.

Breaking Out of the Bubble

Will pentavalent vaccines become the standard in all vaccine schedules the way the MMR and DTP replaced single vaccines? If you don’t think so, consider how difficult it is to find a mumps, measles, or rubella vaccine in any developed nation except Japan. Outside of Japan, they are no longer offered as separate vaccines. Since 2012, GAVI only supports Hep B and HiB as part of the pentavalent vaccine, making a similar restrictive availability more likely to become the standard for the rest of the world.

Further Reading:
Sources: